Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| enzymes | 5066 | 191588-94-0 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A tissue plasminogen activator enzyme that acts as a fibrinolytic agent; it is used for the dissolution of blood clots, such as those that occur in acute MYOCARDIAL INFARCTION.
|
| Dose | Unit | Route |
|---|---|---|
| 40 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 2, 2000 | FDA | GENENTECH | |
| Feb. 23, 2001 | EMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral haemorrhage | 249.78 | 79.88 | 61 | 957 | 34461 | 90592968 |
| Haemorrhage intracranial | 212.76 | 79.88 | 46 | 972 | 15116 | 90612313 |
| Angioedema | 193.81 | 79.88 | 57 | 961 | 64819 | 90562610 |
| Haemorrhagic transformation stroke | 117.46 | 79.88 | 19 | 999 | 1280 | 90626149 |
| Off label use | 85.92 | 79.88 | 81 | 937 | 1102171 | 89525258 |
| Subarachnoid haemorrhage | 81.73 | 79.88 | 22 | 996 | 17882 | 90609547 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral haemorrhage | 217.13 | 60.59 | 69 | 1178 | 38897 | 42581191 |
| No adverse event | 148.77 | 60.59 | 52 | 1195 | 38969 | 42581119 |
| Haemorrhage intracranial | 136.18 | 60.59 | 40 | 1207 | 17152 | 42602936 |
| Haemorrhagic transformation stroke | 135.71 | 60.59 | 26 | 1221 | 1765 | 42618323 |
| Angioedema | 129.52 | 60.59 | 48 | 1199 | 42429 | 42577659 |
| Off label use | 110.94 | 60.59 | 112 | 1135 | 638223 | 41981865 |
| Subarachnoid haemorrhage | 77.62 | 60.59 | 25 | 1222 | 14447 | 42605641 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral haemorrhage | 428.52 | 58.86 | 121 | 2158 | 64847 | 110522173 |
| Angioedema | 309.74 | 58.86 | 104 | 2175 | 98396 | 110488624 |
| Haemorrhage intracranial | 303.99 | 58.86 | 78 | 2201 | 28891 | 110558129 |
| Haemorrhagic transformation stroke | 199.50 | 58.86 | 37 | 2242 | 3000 | 110584020 |
| No adverse event | 173.93 | 58.86 | 63 | 2216 | 73776 | 110513244 |
| Off label use | 156.85 | 58.86 | 171 | 2108 | 1500014 | 109087006 |
| Subarachnoid haemorrhage | 149.44 | 58.86 | 45 | 2234 | 29657 | 110557363 |
| Neurological decompensation | 109.78 | 58.86 | 26 | 2253 | 6857 | 110580163 |
| Cerebral infarction | 84.96 | 58.86 | 34 | 2245 | 51804 | 110535216 |
| Stroke in evolution | 79.82 | 58.86 | 11 | 2268 | 128 | 110586892 |
| Haemorrhage | 72.77 | 58.86 | 38 | 2241 | 106654 | 110480366 |
| Cerebral haematoma | 67.94 | 58.86 | 19 | 2260 | 9613 | 110577407 |
| Pericardial haemorrhage | 64.21 | 58.86 | 16 | 2263 | 5201 | 110581819 |
| Intraventricular haemorrhage | 63.35 | 58.86 | 16 | 2263 | 5491 | 110581529 |
| Hemiparesis | 59.01 | 58.86 | 25 | 2254 | 43878 | 110543142 |
None
| Source | Code | Description |
|---|---|---|
| ATC | B01AD11 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Enzymes |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D005343 | Fibrinolytic Agents |
| MeSH PA | D006401 | Hematologic Agents |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:50249 | anticoagulant |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ankylosing spondylitis | indication | 9631008 | DOID:7147 |
| Acute myocardial infarction | indication | 57054005 | DOID:9408 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Plasminogen | Enzyme | ACTIVATOR | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| WGD229O42W | UNII |
| D06070 | KEGG_DRUG |
| 4021222 | VANDF |
| C0872913 | UMLSCUI |
| CHEBI:753718 | CHEBI |
| CHEMBL2108791 | ChEMBL_ID |
| DB00031 | DRUGBANK_ID |
| D000077785 | MESH_DESCRIPTOR_UI |
| 7769 | INN_ID |
| 259280 | RXNORM |
| 15637 | MMSL |
| 37705 | MMSL |
| d04694 | MMSL |
| 008304 | NDDF |
| 127967007 | SNOMEDCT_US |
| 387066007 | SNOMEDCT_US |
None